<!DOCTYPE html>
<!--[if IE 8]><html class="no-js lt-ie9" lang="en" > <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js" lang="en" > <!--<![endif]-->
<head>
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  
  <meta name="author" content="David Leon (Dawei Leng)">
  <link rel="shortcut icon" href="../img/favicon.ico">
  <title>COVID-19 Drug Discovery Data Analytics - Targeting 2019-nCoV Portal</title>
  <link href='https://fonts.googleapis.com/css?family=Lato:400,700|Roboto+Slab:400,700|Inconsolata:400,700' rel='stylesheet' type='text/css'>

  <link rel="stylesheet" href="../css/theme.css" type="text/css" />
  <link rel="stylesheet" href="../css/theme_extra.css" type="text/css" />
  <link rel="stylesheet" href="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/styles/github.min.css">
  
  <script>
    // Current page data
    var mkdocs_page_name = "COVID-19 Drug Discovery Data Analytics";
    var mkdocs_page_input_path = "Data_analytics.md";
    var mkdocs_page_url = null;
  </script>
  
  <script src="../js/jquery-2.1.1.min.js" defer></script>
  <script src="../js/modernizr-2.8.3.min.js" defer></script>
  <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/highlight.min.js"></script>
  <script>hljs.initHighlightingOnLoad();</script> 
  
</head>

<body class="wy-body-for-nav" role="document">

  <div class="wy-grid-for-nav">

    
    <nav data-toggle="wy-nav-shift" class="wy-nav-side stickynav">
      <div class="wy-side-nav-search">
        <a href=".." class="icon icon-home"> Targeting 2019-nCoV Portal</a>
        <div role="search">
  <form id ="rtd-search-form" class="wy-form" action="../search.html" method="get">
    <input type="text" name="q" placeholder="Search docs" title="Type search term here" />
  </form>
</div>
      </div>

      <div class="wy-menu wy-menu-vertical" data-spy="affix" role="navigation" aria-label="main navigation">
	<ul class="current">
	  
          
            <li class="toctree-l1">
		
    <a class="" href="..">Home</a>
	    </li>
          
            <li class="toctree-l1">
		
    <a class="" href="../drug_candidates/">COVID-19 Clinical Trials</a>
	    </li>
          
            <li class="toctree-l1 current">
		
    <a class="current" href="./">COVID-19 Drug Discovery Data Analytics</a>
    <ul class="subnav">
            
    <li class="toctree-l2"><a href="#data-analysis-for-drug-repositioning">Data analysis for drug repositioning</a></li>
    
        <ul>
        
            <li><a class="toctree-l3" href="#data-analysis-results-from-previous-coronavirus-related-drug-discovery-records">Data analysis results from previous coronavirus related drug discovery records</a></li>
        
            <li><a class="toctree-l3" href="#broad-spectrum-antiviral-data-analysis-results">Broad-spectrum antiviral data analysis results</a></li>
        
            <li><a class="toctree-l3" href="#data-analysis-results-from-previous-other-antiviral-drug-discovery-records">Data analysis results from previous other antiviral drug discovery records</a></li>
        
        </ul>
    

    </ul>
	    </li>
          
            <li class="toctree-l1">
		
    <a class="" href="../computational/">COVID-19 Computational Studies</a>
	    </li>
          
            <li class="toctree-l1">
		
    <a class="" href="../nCov_Targets/">Coronavirus Disease Biology and Therapeutics</a>
	    </li>
          
            <li class="toctree-l1">
		
    <span class="caption-text">Data Download</span>
    <ul class="subnav">
                <li class="">
                    
    <a class="" href="../CoV_Experiment_Data/">Coronavirus Data Mining</a>
                </li>
                <li class="">
                    
    <a class="" href="../nCov_Structures/">COVID-19 Structure Modeling</a>
                </li>
                <li class="">
                    
    <a class="" href="../research_progress/">COVID-19 Research Articles</a>
                </li>
    </ul>
	    </li>
          
            <li class="toctree-l1">
		
    <a class="" href="../ghddi_news/">COVID-19 GHDDI News</a>
	    </li>
          
            <li class="toctree-l1">
		
    <a class="" href="../contact_us/">COVID-19 Community Discussion</a>
	    </li>
          
            <li class="toctree-l1">
		
    <a class="" href="../useful_links/">COVID-19 Useful Links</a>
	    </li>
          
            <li class="toctree-l1">
		
    <a class="" href="../history/">Github History</a>
	    </li>
          
        </ul>
      </div>
      &nbsp;
    </nav>

    <section data-toggle="wy-nav-shift" class="wy-nav-content-wrap">

      
      <nav class="wy-nav-top" role="navigation" aria-label="top navigation">
        <i data-toggle="wy-nav-top" class="fa fa-bars"></i>
        <a href="..">Targeting 2019-nCoV Portal</a>
      </nav>

      
      <div class="wy-nav-content">
        <div class="rst-content">
          <div role="navigation" aria-label="breadcrumbs navigation">
  <ul class="wy-breadcrumbs">
    <li><a href="..">Docs</a> &raquo;</li>
    
      
    
    <li>COVID-19 Drug Discovery Data Analytics</li>
    <li class="wy-breadcrumbs-aside">
      
    </li>
  </ul>
  <hr/>
</div>
          <div role="main">
            <div class="section">
              
                <h1 id="data-analysis-for-drug-repositioning">Data analysis for drug repositioning</h1>
<p>A comprehensive data mining and analysis effort has been done to present these lists of existing drugs with therapeutic potentials for COVID-19. The analysis was based on different rationales including anti-coronavirus activity, broad-spectrum antiviral activity and antiviral drugs with highly conserved viral target such as RNA dependent RNA polymerase (RDRP). We will constantly update these lists with new discoveries. </p>
<h2 id="data-analysis-results-from-previous-coronavirus-related-drug-discovery-records">Data analysis results from previous coronavirus related drug discovery records</h2>
<p>A collection of drug candidates with previously published positive coronavirus experimental results.</p>
<table>
<thead>
<tr>
<th>Drug name</th>
<th>DrugBank ID</th>
<th>Mechanism of action</th>
<th>Experimental activity</th>
<th>Methods</th>
<th>Measurement</th>
<th>Value</th>
<th>Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remdesivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB14761">DB14761</a></td>
<td>Nucleobindin-1 (NUCB1) Inhibitors</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>1.00E-08</td>
<td>M</td>
</tr>
<tr>
<td>Emetine</td>
<td><a href="https://www.drugbank.ca/drugs/DB13393">DB13393</a></td>
<td>Platelet-Derived Growth Factor (PDGF) Inhibitors;Signal Transduction Modulators;Angiogenesis Inhibitors</td>
<td>Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO</td>
<td>Cytopathicity assay</td>
<td>IC-50</td>
<td>1.50E-07</td>
<td>M</td>
</tr>
<tr>
<td>Nafamostat mesilate</td>
<td><a href="https://www.drugbank.ca/drugs/DB12598">DB12598</a></td>
<td>Tryptase Inhibitors</td>
<td>Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO</td>
<td>Vero cells (TMPRSS2-expressing) transfected with MERS</td>
<td>IC-50</td>
<td>1.00E-09</td>
<td>M</td>
</tr>
<tr>
<td>Alisporivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB12139">DB12139</a></td>
<td>P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Cyclophilin Inhibitors</td>
<td>Coronavirus acute respiratory syndrome remission/reduction, IN VITRO</td>
<td>RNA assay</td>
<td>IC-50</td>
<td>8.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Niclosamide</td>
<td><a href="https://www.drugbank.ca/drugs/DB06803">DB06803</a></td>
<td>Cytochrome P450 CYP1A2 Inhibitors;Quorum Sensing (Pseudomonas aeruginosa) Inhibitors;Neuropeptide Y4 (NPY Y4) Receptor Positive Allosteric Modulators;Autophagy Inducers;Wnt Signaling Inhibitors</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Cytopathicity assay</td>
<td>IC-50</td>
<td>1.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Rupintrivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB05102">DB05102</a></td>
<td>HRV 3C Protease Inhibitors</td>
<td>Coronavirus acute respiratory syndrome remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>3.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Geldanamycin</td>
<td><a href="https://www.drugbank.ca/drugs/DB02424">DB02424</a></td>
<td>Signal Transduction Modulators;Heat Shock Protein 90 (Hsp90) Inhibitors</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td></td>
<td>IC-50</td>
<td>9.10E-07</td>
<td>M</td>
</tr>
<tr>
<td>Sinefungin</td>
<td><a href="https://www.drugbank.ca/drugs/DB01910">DB01910</a></td>
<td>Coactivator Associated Arginine Methyltransferase 1 (CARM1; PRMT4) Inhibitors;Histone-Lysine N-Methyltransferase SETD7 (SET7/9) Inhibitors;Protein-L-Isoaspartate(D-Aspartate) O-Methyltransferase (PCMT1; PIMT) Inhibitors;Epigenetic Modifier Modulators</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td></td>
<td>IC-50</td>
<td>3.83E-07</td>
<td>M</td>
</tr>
<tr>
<td>Mycophenolic acid sodium salt</td>
<td><a href="https://www.drugbank.ca/drugs/DB01024">DB01024</a></td>
<td>Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors</td>
<td>Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO</td>
<td>Cytopathicity assay</td>
<td>IC-50</td>
<td>1.70E-07</td>
<td>M</td>
</tr>
<tr>
<td>Mycophenolate mofetil</td>
<td><a href="https://www.drugbank.ca/drugs/DB00688">DB00688</a></td>
<td>Hydroxycarboxylic Acid Receptor 2 (HCAR2; NIACR1; GPR109A) Agonists;Signal Transduction Modulators;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors</td>
<td>Coronavirus acute respiratory syndrome remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>2.30E-07</td>
<td>M</td>
</tr>
<tr>
<td>Chloroquine</td>
<td><a href="https://www.drugbank.ca/drugs/DB00608">DB00608</a></td>
<td></td>
<td>Coronavirus acute respiratory syndrome remission/reduction, IN VITRO</td>
<td></td>
<td>IC-50</td>
<td>8.00E-10</td>
<td>M</td>
</tr>
<tr>
<td>Gemcitabine hydrochloride</td>
<td><a href="https://www.drugbank.ca/drugs/DB00441">DB00441</a></td>
<td>Ribonucleoside-Diphosphate Reductase Inhibitors;Pyrimidine Antagonists</td>
<td>Coronavirus acute respiratory syndrome remission/reduction, IN VITRO</td>
<td>Cytopathicity assay</td>
<td>IC-50</td>
<td>4.40E-07</td>
<td>M</td>
</tr>
<tr>
<td>Promazine</td>
<td><a href="https://www.drugbank.ca/drugs/DB00420">DB00420</a></td>
<td>Signal Transduction Modulators;Dopamine Receptor Antagonists</td>
<td>Coronavirus acute respiratory syndrome remission/reduction, IN VITRO</td>
<td>Cytopathicity assay</td>
<td>MIC</td>
<td>1.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Azithromycin</td>
<td><a href="https://www.drugbank.ca/drugs/DB00207">DB00207</a></td>
<td>Nonsense Mutation Suppressors;50S Ribosomal Protein Inhibitors</td>
<td>Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO</td>
<td>Luciferine/luciferase assay</td>
<td>IC-50</td>
<td>1.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>cyclosporin</td>
<td><a href="https://www.drugbank.ca/drugs/DB00091">DB00091</a></td>
<td>Cyclophilin Inhibitors;Mitochondrial Permeability Transition (MPT) Inhibitors</td>
<td>Coronavirus acute respiratory syndrome remission/reduction, IN VITRO</td>
<td>RNA assay</td>
<td>IC-50</td>
<td>8.00E-07</td>
<td>M</td>
</tr>
</tbody>
</table>
<h2 id="broad-spectrum-antiviral-data-analysis-results">Broad-spectrum antiviral data analysis results</h2>
<p>Based on in vitro viral infection assay results (EC50&lt;=1uM) and clinical data (in vivo active) we have identified:</p>
<ol>
<li>
<p>469 molecules against at least 2 virus species</p>
</li>
<li>
<p><a href="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/BroadAntivirusDrugProfile-top51.csv">51 molecules against at least 5 virus species</a> <img alt="Top 51 DVI graph" src="http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/Top51BSAAs.png" /></p>
</li>
<li>
<p>10 molecules against at least 10 virus species</p>
</li>
</ol>
<table>
<thead>
<tr>
<th>ï»¿Drug name</th>
<th>Drug ID</th>
<th>Number of virus speices</th>
<th>Virus species list</th>
<th>Discovered MOA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenofovir</td>
<td><a href="https://www.drugbank.ca/drugs/DB14126">DB14126</a></td>
<td>15</td>
<td>FLUAV;HCV;HBV;HSV;HSV-2;HIV-1;HIV-2;ADV;DENV;RSV;CMV;VZV;Parainfluenza virus;Rhinovirus;Xenotropic murine leukemia virus-related virus</td>
<td>Nucleotide reverse transcriptase inhibitor</td>
</tr>
<tr>
<td>Nitazoxanide</td>
<td><a href="https://www.drugbank.ca/drugs/DB00507">DB00507</a></td>
<td>13</td>
<td>MERS-CoV;ZIKV;FLUAV;FLUBV;HBV;HCV;HIV-1;DENV;RSV;ADV;NoV;RuV;JEV</td>
<td>Hemagglutinin inhibitor</td>
</tr>
<tr>
<td>Mycophenolic acid</td>
<td><a href="https://www.drugbank.ca/drugs/DB01024">DB01024</a></td>
<td>13</td>
<td>MERS-CoV;CoV;ZIKV;DENV;HCV;FLUAV;FLUBV;WNV;RSV;BKV;Avian flu;Filovirus;Parainfluenza virus</td>
<td>Dehydrogenase</td>
</tr>
<tr>
<td>Brincidofovir</td>
<td><a href="https://www.drugbank.ca/drugs/DB12151">DB12151</a></td>
<td>13</td>
<td>EBOV;CMV;HSV;VZV;BKV;ADV;EBV;HTLV-1;HPV;HSV-1;HSV-6;VACV;JC polyomavirus</td>
<td>DNA polymerase Inhibitor</td>
</tr>
<tr>
<td>Ribavirin</td>
<td><a href="https://www.drugbank.ca/drugs/DB00811">DB00811</a></td>
<td>11</td>
<td>FLU;FLUAV;FLUBV;HCV;RSV;EV;HSV;HEV;LASV;Avian flu;Parainfluenza virus</td>
<td>Inosine monophosphate dehydrogenase inhibitor; RNA-dependent RNA polymerase inhibitor</td>
</tr>
<tr>
<td></td>
<td><a href="https://pubchem.ncbi.nlm.nih.gov/compound/5480370">CID:5480370</a></td>
<td>11</td>
<td>FLUAV;DENV;HBV;HCV;HSV;ADV;RSV;CMV;VZV;Rhinovirus;Parainfluenza virus</td>
<td></td>
</tr>
<tr>
<td>Remdesivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB14761">DB14761</a></td>
<td>10</td>
<td>CoV;SARS-CoV;MERS-CoV;2019nCoV;EBOV;ZIKV;MARV;HCV;RSV;Filovirus</td>
<td>RNA polymerase inhibitor</td>
</tr>
<tr>
<td>Tilorone</td>
<td><a href="https://www.drugbank.ca/drugs/DB09070">DB09070</a></td>
<td>10</td>
<td>MERS-CoV;EBOV;HBV;HCV;CHIKV;CMV;HAV;HSV-1;MARV;WNV</td>
<td>Interferon inducers</td>
</tr>
<tr>
<td>Cidofovir</td>
<td><a href="https://www.drugbank.ca/drugs/DB00369">DB00369</a></td>
<td>10</td>
<td>HPV;CMV;HSV;EBV;VZV;ADV;BKV;HSV-1;HSV-2;JC polyomavirus</td>
<td>DNA polymerase Inhibitor</td>
</tr>
<tr>
<td></td>
<td><a href="https://pubchem.ncbi.nlm.nih.gov/compound/71761402">CID:71761402</a></td>
<td>10</td>
<td>SARS-CoV;FLUAV;FLUBV;DENV;ADV;RSV;WNV;Filovirus;Rhinovirus;Parainfluenza virus</td>
<td></td>
</tr>
</tbody>
</table>
<h2 id="data-analysis-results-from-previous-other-antiviral-drug-discovery-records">Data analysis results from previous other antiviral drug discovery records</h2>
<p>A collection of drug candidates in pipelines or marketed for different antiviral indications. All candidates have at least completed Phase I studies. However, not all have in vitro anti-coronavirus or anti-2019nCoV evidence yet, further studies using 2019-nCoV specific assays are required to evaluate their anti-2019nCoV potential. </p>
<h3 id="1-antiviral-candidates-selected-from-viral-replication-assay">1. Antiviral candidates selected from viral replication assay</h3>
<table>
<thead>
<tr>
<th>Drug name</th>
<th>DrugBank ID</th>
<th>Clinical Information</th>
<th>Mechanism of action</th>
<th>Experimental activity</th>
<th>Method</th>
<th>Measurement</th>
<th>Value</th>
<th>Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deferiprone</td>
<td><a href="https://www.drugbank.ca/drugs/DB08826">DB08826</a></td>
<td>1. Phase 4 completed  for acute iron intoxication <br/>2. Phase 4 completed for Hepatic impairment <br/>3.  Phase 4 completed for impaired kidney function <br/>4. Phase 4 completed for  Beta-Thalassemia <br/>5. Phase 4 completed for hemosiderosis <br/>6. Phase 4  completed for Prolonged QT Interval <br/>7. Phase III completed for Parkinson's  disease; <br/>Marketed for iron toxicity</td>
<td>Chelating Agents;Cytochrome P450 CYP4F2 Inhibitors</td>
<td>Infection, BK polyomavirus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>3.50E-09</td>
<td>M</td>
</tr>
<tr>
<td>Raltegravir potassium</td>
<td><a href="https://www.drugbank.ca/drugs/DB06817">DB06817</a></td>
<td>Phase 4 completed  for HIV <br/>Marketed for Anti-Retroviral HIV</td>
<td>HIV Integrase Inhibitors</td>
<td>Infection, xenotropic murine leukemia virus-related virus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>5.00E-9</td>
<td>M</td>
</tr>
<tr>
<td>Verdinexor</td>
<td><a href="https://www.drugbank.ca/drugs/DB12207">DB12207</a></td>
<td>Phase 1 completed  for basic science on health volunteers</td>
<td>Exportin-1 (CRM1, XPO1) Receptor Antagonists;Signal Transduction Modulators</td>
<td>Infection, JC polyomavirus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>7.50E-09</td>
<td>M</td>
</tr>
<tr>
<td>Brincidofovir</td>
<td><a href="https://www.drugbank.ca/drugs/DB12151">DB12151</a></td>
<td>Phase 3 completed  for adenovirus infections</td>
<td>DNA Polymerase Inhibitors</td>
<td>Infection, JC polyomavirus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>2.00E-8</td>
<td>M</td>
</tr>
<tr>
<td>Remdesivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB14761">DB14761</a></td>
<td>1. Phase III for  Ebola <br>2. Phase III for nCoV</td>
<td>Nucleobindin-1 (NUCB1) Inhibitors</td>
<td>Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>2.50E-8</td>
<td>M</td>
</tr>
<tr>
<td>Verdinexor</td>
<td><a href="https://www.drugbank.ca/drugs/DB12207">DB12207</a></td>
<td>Phase I completed  for basic science experiments on healthy volunteers</td>
<td>Exportin-1 (CRM1, XPO1) Receptor Antagonists;Signal Transduction Modulators</td>
<td>Infection, adenovirus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>3.00E-8</td>
<td>M</td>
</tr>
<tr>
<td>Cidofovir</td>
<td><a href="https://www.drugbank.ca/drugs/DB00369">DB00369</a></td>
<td>Phase 4 completed  for cytomegalovirus <br/>Marketed for CMV in AIDS patients</td>
<td>DNA Polymerase Inhibitors</td>
<td>Infection, cytomegalovirus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-99</td>
<td>6.00E-8</td>
<td>M</td>
</tr>
<tr>
<td>Alvocidib hydrochloride</td>
<td><a href="https://www.drugbank.ca/drugs/DB03496">DB03496</a></td>
<td>1. Phase II  completed for sarcomas <br>2. Phase II completed for renal cancers; <br>3. Phase II  completed for melanoma <br>4. Phase II completed for other cancers including:  myeloma, carcinoma, esophageal, endometrial, leukaemia, etc.</td>
<td>Cyclin-Dependent Kinase 1 (CDK1) Inhibitors;Signal Transduction Modulators;Cyclin-Dependent Kinase 6 (CDK6) Inhibitors;CDK9/Cyclin T1 Inhibitors;Baculoviral IAP Repeat-Containing Protein 5 (BIRC5; Survivin) Inhibitors;Apoptosis Inducers;Cyclin-Dependent Kinase 7 (CDK7) Inhibitors;Cyclin-Dependent Kinase 2 (CDK2) Inhibitors;Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Inhibitors;Cyclin-Dependent Kinase 4 (CDK4) Inhibitors;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors;Apoptosis Regulator Bcl-2 Inhibitors</td>
<td>Infection, herpes virus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>1.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Ganciclovir</td>
<td><a href="https://www.drugbank.ca/drugs/DB01004">DB01004</a></td>
<td>1. Phase 4 active  for viral pneumonia <br>2. Phase 4 completed for DNA virus infections <br>3. Phase 4  completed for CMV <br>4. Phase 4 completed for viral sepsis</td>
<td>DNA Polymerase Inhibitors</td>
<td>Infection, herpes simplex virus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>1.00E-8</td>
<td>M</td>
</tr>
</tbody>
</table>
<h3 id="2-antiviral-candidates-selected-from-different-in-vitro-assays">2. Antiviral candidates selected from different in vitro assays</h3>
<table>
<thead>
<tr>
<th>Drug_name</th>
<th>DrugBank  ID</th>
<th>Clinical Information</th>
<th>Mechanism of action</th>
<th>Experimental activity</th>
<th>Method</th>
<th>Measurement</th>
<th>Value</th>
<th>Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presatovir</td>
<td><a href="https://www.drugbank.ca/drugs/DB12165">DB12165</a></td>
<td>Phase II completed  for Respiratory Syncytial Virus</td>
<td>Respiratory Syncytial Virus (RSV) Fusion Inhibitors;Viral Fusion Inhibitors</td>
<td>Infection, respiratory syncytial virus (RSV) remission/reduction, IN VITRO</td>
<td>Cytopathicity assay</td>
<td>IC-50</td>
<td>1.80E-12</td>
<td>M</td>
</tr>
<tr>
<td>Brincidofovir</td>
<td><a href="https://www.drugbank.ca/drugs/DB12151">DB12151</a></td>
<td>Phase III completed  for AdV, BKV, CMV, EBV, and HHV6</td>
<td>DNA Polymerase Inhibitors</td>
<td>Infection, cytomegalovirus remission/reduction, IN VITRO</td>
<td>DNA assay</td>
<td>IC-50</td>
<td>2.00E-12</td>
<td>M</td>
</tr>
<tr>
<td>Sorivudine</td>
<td><a href="https://www.drugbank.ca/drugs/DB11998">DB11998</a></td>
<td>Phase III  completed for Chickenpox, HIV</td>
<td>DNA Polymerase Inhibitors</td>
<td>Infection, varicella zoster virus remission/reduction, IN VITRO</td>
<td>Plaque assay</td>
<td>IC-50</td>
<td>2.40E-11</td>
<td>M</td>
</tr>
<tr>
<td>Peramivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB06614">DB06614</a></td>
<td>Phase 4 completed  for influenza <br/>Marketed for influenza</td>
<td>Neuraminidase (Sialidase) (Influenza Virus) Inhibitors</td>
<td>Neuraminidase (nonspecified subtype) (Influenza A virus) inhibition, IN VITRO</td>
<td>4-Methylumbelliferyl-N-acetyl-alpha-D-neuraminic acid as substrate</td>
<td>Ki</td>
<td>1.40E-11</td>
<td>M</td>
</tr>
<tr>
<td>Peramivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB06614">DB06614</a></td>
<td>Phase 4 completed  for influenza <br/>Marketed for influenza</td>
<td>Neuraminidase (Sialidase) (Influenza Virus) Inhibitors</td>
<td>Neuraminidase (nonspecified subtype) (Influenza A virus) inhibition, IN VITRO</td>
<td>4-Methylumbelliferyl-N-acetyl-alpha-D-neuraminic acid as substrate</td>
<td>IC-50</td>
<td>5.00E-11</td>
<td>M</td>
</tr>
<tr>
<td>Zanamivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB00558">DB00558</a></td>
<td>Phase 4 completed  for influenza <br/>Marketed for influenza</td>
<td>Neuraminidase (Sialidase) (Influenza Virus) Inhibitors</td>
<td>Neuraminidase (nonspecified subtype) (Influenza A virus) inhibition, IN VITRO</td>
<td>Chemiluminescent assay</td>
<td>IC-50</td>
<td>3.00E-11</td>
<td>M</td>
</tr>
<tr>
<td>Sirolimus</td>
<td><a href="https://www.drugbank.ca/drugs/DB00877">DB00877</a></td>
<td>1. Phase 4 completed  for renal diseases, renal failure <br>2. Phase 4 completed for kidney and heart  transplatation <br/>Marketed for kidney transplantation</td>
<td>CCR5 Expression Inhibitors;Cytochrome P450 CYP2D6 Inhibitors;Signal Transduction Modulators;Cytochrome P450 CYP2C9 Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Proteasome Inhibitors;Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;Drugs Targeting B-Lymphocyte Antigen CD19</td>
<td>Infection, cytomegalovirus remission/reduction, IN VITRO</td>
<td>Chemiluminescent assay</td>
<td>IC-50</td>
<td>4.00E-11</td>
<td>M</td>
</tr>
<tr>
<td>Laninamivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB12791">DB12791</a></td>
<td>Phase I completed  for influenza</td>
<td>Neuraminidase (Sialidase) (Influenza Virus) Inhibitors</td>
<td>Neuraminidase (nonspecified subtype) (Influenza A virus) inhibition, IN VITRO</td>
<td>Fluorescent assay</td>
<td>IC-50</td>
<td>1.10E-10</td>
<td>M</td>
</tr>
<tr>
<td>Ribavirin</td>
<td><a href="https://www.drugbank.ca/drugs/DB00811">DB00811</a></td>
<td>1. nCoV clinical  trial <br>2. Phase 4 completed for HCV <br>3. Phase 3 completed for HBV <br/>Marketed for RSV, HCV,</td>
<td>Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Equilibrative Nucleoside Transporter ENT1 Inhibitors</td>
<td>Infection, respiratory syncytial virus (RSV) remission/reduction, IN VITRO</td>
<td>ELISA assay</td>
<td>IC-50</td>
<td>1.26E-10</td>
<td>M</td>
</tr>
</tbody>
</table>
<hr />
<h3 id="3-top-antiviral-candidates-with-rdrp-inhibition-moa-selected-from-different-assays">3. Top antiviral candidates with RDRP inhibition MOA selected from different assays</h3>
<table>
<thead>
<tr>
<th>Drug name</th>
<th>DrugBank ID</th>
<th>Mechanism of action</th>
<th>Experimental activity</th>
<th>Measurement</th>
<th>Value</th>
<th>Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beclabuvir</td>
<td><a href="https://www.drugbank.ca/drugs/DB12225">DB12225</a></td>
<td>RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors</td>
<td>Hepatitis C (HCV) remission/reduction, IN VITRO</td>
<td>IC-50</td>
<td>3.00E-09</td>
<td>M</td>
</tr>
<tr>
<td>Remdesivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB14761">DB14761</a></td>
<td>RNA-Dependent RNA Polymerase Inhibitor</td>
<td>Ebola virus disease remission/reduction, IN VITRO</td>
<td>IC-50</td>
<td>1.00E-08</td>
<td>M</td>
</tr>
<tr>
<td>Valopicitabine</td>
<td><a href="https://www.drugbank.ca/drugs/DB13920">DB13920</a></td>
<td>RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors</td>
<td>Hepatitis C (HCV) remission/reduction, IN VITRO</td>
<td>IC-50</td>
<td>9.00E-08</td>
<td>M</td>
</tr>
<tr>
<td>Mericitabine</td>
<td><a href="https://www.drugbank.ca/drugs/DB12045">DB12045</a></td>
<td>RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors</td>
<td>Hepatitis C (HCV) remission/reduction, IN VITRO</td>
<td>IC-50</td>
<td>1.30E-07</td>
<td>M</td>
</tr>
<tr>
<td>Lumicitabine</td>
<td><a href="https://www.drugbank.ca/drugs/DB14808">DB14808</a></td>
<td>RNA-Dependent RNA Polymerase (Respiratory Syncytial Virus) Inhibitors</td>
<td>Infection, respiratory syncytial virus (RSV) remission/reduction, IN VITRO</td>
<td>IC-50</td>
<td>2.60E-07</td>
<td>M</td>
</tr>
<tr>
<td>Sofosbuvir</td>
<td><a href="https://www.drugbank.ca/drugs/DB08934">DB08934</a></td>
<td>RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors</td>
<td>Infection, dengue virus remission/reduction, IN VITRO</td>
<td>IC-90</td>
<td>4.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Adafosbuvir</td>
<td><a href="https://www.drugbank.ca/drugs/DB14906">DB14906</a></td>
<td>RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors</td>
<td>Infection, dengue virus remission/reduction, IN VITRO</td>
<td>IC-50</td>
<td>1.10E-06</td>
<td>M</td>
</tr>
</tbody>
</table>
<p>*Compounds selected based on top PX scores from respective assays.</p>
              
            </div>
          </div>
          <footer>
  
    <div class="rst-footer-buttons" role="navigation" aria-label="footer navigation">
      
        <a href="../computational/" class="btn btn-neutral float-right" title="COVID-19 Computational Studies">Next <span class="icon icon-circle-arrow-right"></span></a>
      
      
        <a href="../drug_candidates/" class="btn btn-neutral" title="COVID-19 Clinical Trials"><span class="icon icon-circle-arrow-left"></span> Previous</a>
      
    </div>
  

  <hr/>

  <div role="contentinfo">
    <!-- Copyright etc -->
    
  </div>

  Built with <a href="http://www.mkdocs.org">MkDocs</a> using a <a href="https://github.com/snide/sphinx_rtd_theme">theme</a> provided by <a href="https://readthedocs.org">Read the Docs</a>.
</footer>
      
        </div>
      </div>

    </section>

  </div>

  <div class="rst-versions" role="note" style="cursor: pointer">
    <span class="rst-current-version" data-toggle="rst-current-version">
      
      
        <span><a href="../drug_candidates/" style="color: #fcfcfc;">&laquo; Previous</a></span>
      
      
        <span style="margin-left: 15px"><a href="../computational/" style="color: #fcfcfc">Next &raquo;</a></span>
      
    </span>
</div>
    <script>var base_url = '..';</script>
    <script src="../js/theme.js" defer></script>
      <script src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML" defer></script>
      <script src="../search/main.js" defer></script>

</body>
</html>
